Pneumococcal Glycoconjugate Vaccine Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Streptococcus pneumoniae serotype 12F are limited in their ability to be produced in high quantities safely and effectively, and there is a need for improved immunogenic compositions that can provide better protection against invasive pneumococcal diseases.
Innovation Solution
Development of isolated Streptococcus pneumoniae serotype 12F polysaccharide and glycoconjugates with specific compositions, including varying ratios of N-acetylgalactosamine and 4-keto-N-acetyl-quinovosamine residues, which are used to create immunogenic compositions and vaccines through activation and conjugation with carrier proteins, enhancing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional vaccine production methods are used for Streptococcus pneumoniae serotype 12F, then production can be maintained at current levels, but the ability to produce high quantities safely and effectively is limited
Solution Approach 1:
The patent modifies the chemical structure of the polysaccharide antigen by controlling the ratio of N-acetylgalactosamine to 4-keto-N-acetyl-quinovosamine residues (within specific ranges: 99.9:0.1 to 50:50), and adjusts molecular weight parameters (50-2000 kDa), thereby changing the immunogenic properties to achieve both high productivity and reliability in vaccine production
Solution Approach 2:
The patent creates glycoconjugate vaccines by chemically conjugating the purified polysaccharide antigen with carrier proteins (such as CRM197, tetanus toxoid, or diphtheria toxoid), forming composite materials that enhance both the safety and effectiveness while enabling large-scale production
2Reliability
If polysaccharide composition is modified to enhance immunogenicity, then immune response is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent establishes specific parameter ranges for the polysaccharide structure (sugar residue ratios and molecular weight) that optimize immunogenicity while remaining feasible for manufacturing, balancing immune response enhancement with production capabilities
Solution Approach 2:
The patent implements quality control measures including HPLC, NMR, and mass spectrometry to monitor and adjust polysaccharide composition during production, ensuring consistent immunogenicity while maintaining manufacturing precision through real-time feedback
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel polysaccharide and glycoconjugate compositions provide enhanced immunogenicity and safety for large-scale vaccine production, effectively eliciting immune responses and potentially improving protection against pneumococcal infections.
Implementation Method 1
The novel polysaccharide and glycoconjugate compositions provide enhanced immunogenicity and safety for large-scale vaccine production, effectively eliciting immune responses
Data Source
AI summary
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.